Illumina, Inc. vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Illumina, Inc. trades at $181.14 (market cap $27.94B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.52. The key difference: Illumina, Inc. is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | XDTE | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $194.33 | $44.76 |
52-Week Low | $91.00 | $36.00 |
Enterprise Value | $29.33B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
XDTE (Roundhill S&P 500 0DTE Covered Call Strategy ETF) trades at $38.44, down 0.1% with a bearish technical signal. The ETF generates income through daily options strategies but faces concerns about net asset value erosion despite high dividend yields. Recent news highlights the fund's 32% yield but questions its sustainability as the math may not hold up over time.
The outlook remains cautious due to structural risks in the covered call strategy potentially limiting upside during market rallies. While offering frequent distributions, investors face the risk of underperforming the underlying S&P 500 index during strong bull markets. The fund's viability depends on market volatility conditions favorable to options selling strategies.
Trailing returns across standard periods
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →